Read by QxMD icon Read

IBD Linx

shared collection
188 papers 25 to 100 followers Key articles related to inflammatory bowel disease
By Mark Mattar IBD specialist, educator
Loren Laine, Tonya Kaltenbach, Alan Barkun, Kenneth R McQuaid, Venkataraman Subramanian, Roy Soetikno
No abstract text is available yet for this article.
March 2015: Gastroenterology
Glen S Hazlewood, Ali Rezaie, Meredith Borman, Remo Panaccione, Subrata Ghosh, Cynthia H Seow, Ellen Kuenzig, George Tomlinson, Corey A Siegel, Gil Y Melmed, Gilaad G Kaplan
BACKGROUND & AIMS: There is controversy regarding the best treatment for patients with Crohn's disease because of the lack of direct comparative trials. We compared therapies for induction and maintenance of remission in patients with Crohn's disease, based on direct and indirect evidence. METHODS: We performed systematic reviews of MEDLINE, EMBASE, and Cochrane Central databases, through June 2014. We identified randomized controlled trials (N = 39) comparing methotrexate, azathioprine/6-mercaptopurine, infliximab, adalimumab, certolizumab, vedolizumab, or combined therapies with placebo or an active agent for induction and maintenance of remission in adult patients with Crohn's disease...
February 2015: Gastroenterology
Peter De Cruz, Michael A Kamm, Amy L Hamilton, Kathryn J Ritchie, Efrosinia O Krejany, Alexandra Gorelik, Danny Liew, Lani Prideaux, Ian C Lawrance, Jane M Andrews, Peter A Bampton, Peter R Gibson, Miles Sparrow, Rupert W Leong, Timothy H Florin, Richard B Gearry, Graham Radford-Smith, Finlay A Macrae, Henry Debinski, Warwick Selby, Ian Kronborg, Michael J Johnston, Rodney Woods, P Ross Elliott, Sally J Bell, Steven J Brown, William R Connell, Paul V Desmond
BACKGROUND: Most patients with Crohn's disease need an intestinal resection, but a majority will subsequently experience disease recurrence and require further surgery. This study aimed to identify the optimal strategy to prevent postoperative disease recurrence. METHODS: In this randomised trial, consecutive patients from 17 centres in Australia and New Zealand undergoing intestinal resection of all macroscopic Crohn's disease, with an endoscopically accessible anastomosis, received 3 months of metronidazole therapy...
April 11, 2015: Lancet
Ruben J Colman, David T Rubin
BACKGROUND AND AIMS: Fecal microbiota transplantation (FMT) has gained interest as a novel treatment option for inflammatory bowel diseases (IBD). While publications describing FMT as therapy for IBD have more than doubled since 2012, research that investigates FMT treatment efficacy has been scarce. We conducted a systematic review and meta-analysis to evaluate the efficacy of FMT as treatment for patients with IBD. METHODS: A systematic literature search was performed through May 2014...
December 2014: Journal of Crohn's & Colitis
Filip Baert, David Drobne, Ann Gils, Niels Vande Casteele, Scott Hauenstein, Sharat Singh, Steve Lockton, Paul Rutgeerts, Séverine Vermeire
BACKGROUND & AIMS: Few agents are available for the treatment of inflammatory bowel diseases, and patients frequently become unresponsive to biologics. We investigated the feasibility of reinitiating infliximab therapy for patients who previously received only episodic therapy with, lost response to, or had infusion reactions to infliximab. We also aimed to identify factors associated with the success and safety of restarting infliximab, such as antibodies to infliximab and trough levels of the drug...
September 2014: Clinical Gastroenterology and Hepatology
Mahmoud H Mosli, William J Sandborn, Richard B Kim, Reena Khanna, Bandar Al-Judaibi, Brian G Feagan
The medical management of inflammatory bowel disease (IBD) is evolving toward a personalized medicine-based model. Modern therapeutic algorithms that feature use of tumor necrosis factor (TNF) antagonists in combination with immunosuppressive are highly effective when initiated in high-risk patients early in the course of disease. Defined targets that guide intensification of therapy are critical interventions. In this model, therapy is optimized through appropriate pretreatment testing, therapeutic drug monitoring, and patient-based monitoring strategies...
July 2014: American Journal of Gastroenterology
William J Sandborn, Brian G Feagan, Paul Rutgeerts, Stephen Hanauer, Jean-Frédéric Colombel, Bruce E Sands, Milan Lukas, Richard N Fedorak, Scott Lee, Brian Bressler, Irving Fox, Maria Rosario, Serap Sankoh, Jing Xu, Kristin Stephens, Catherine Milch, Asit Parikh
BACKGROUND: The efficacy of vedolizumab, an α4β7 integrin antibody, in Crohn's disease is unknown. METHODS: In an integrated study with separate induction and maintenance trials, we assessed intravenous vedolizumab therapy (300 mg) in adults with active Crohn's disease. In the induction trial, 368 patients were randomly assigned to receive vedolizumab or placebo at weeks 0 and 2 (cohort 1), and 747 patients received open-label vedolizumab at weeks 0 and 2 (cohort 2); disease status was assessed at week 6...
August 22, 2013: New England Journal of Medicine
Brian G Feagan, Paul Rutgeerts, Bruce E Sands, Stephen Hanauer, Jean-Frédéric Colombel, William J Sandborn, Gert Van Assche, Jeffrey Axler, Hyo-Jong Kim, Silvio Danese, Irving Fox, Catherine Milch, Serap Sankoh, Tim Wyant, Jing Xu, Asit Parikh
BACKGROUND: Gut-selective blockade of lymphocyte trafficking by vedolizumab may constitute effective treatment for ulcerative colitis. METHODS: We conducted two integrated randomized, double-blind, placebo-controlled trials of vedolizumab in patients with active disease. In the trial of induction therapy, 374 patients (cohort 1) received vedolizumab (at a dose of 300 mg) or placebo intravenously at weeks 0 and 2, and 521 patients (cohort 2) received open-label vedolizumab at weeks 0 and 2, with disease evaluation at week 6...
August 22, 2013: New England Journal of Medicine
Aleksandar D Kostic, Ramnik J Xavier, Dirk Gevers
Studies of the roles of microbial communities in the development of inflammatory bowel disease (IBD) have reached an important milestone. A decade of genome-wide association studies and other genetic analyses have linked IBD with loci that implicate an aberrant immune response to the intestinal microbiota. More recently, profiling studies of the intestinal microbiome have associated the pathogenesis of IBD with characteristic shifts in the composition of the intestinal microbiota, reinforcing the view that IBD results from altered interactions between intestinal microbes and the mucosal immune system...
May 2014: Gastroenterology
Matthew D Rutter, Robert H Riddell
Surveillance for neoplasia in colitis is the most challenging diagnostic colonoscopic procedure. The detection and treatment of colorectal dysplasia in inflammatory bowel disease remain problematic to the point that unsuspected colorectal cancers (CRCs) are still identified. Excellent bowel preparation and use of high-resolution colonoscopes with chromoendoscopy facilitate the detection and characterization of subtle neoplasia. This approach is superior to taking random biopsy specimens and should be the standard of care for surveillance but requires adequate training...
March 2014: Clinical Gastroenterology and Hepatology
Gary R Lichtenstein, Brian G Feagan, Russell D Cohen, Bruce A Salzberg, Robert H Diamond, Wayne Langholff, Anil Londhe, William J Sandborn
OBJECTIVES: We assessed potential associations between malignancy and antitumor necrosis factor therapy in patients with Crohn's disease (CD), as this relationship is currently poorly defined. METHODS: Utilizing data from the Crohn's Therapy, Resource, Evaluation, and Assessment Tool (TREAT™) Registry, a prospective cohort study examining long-term outcomes of CD treatments in community and academic settings, influences of baseline patient/disease characteristics and medications were assessed by survival analysis and multivariate models...
February 2014: American Journal of Gastroenterology
Ryan Nelson, Chuanhong Liao, Alessandro Fichera, David T Rubin, Joel Pekow
BACKGROUND: Cyclosporine and infliximab (IFX) are effective medical therapies for inducing remission in patients with steroid-refractory ulcerative colitis (UC). Patients with acute severe disease who do not respond to these therapies require colectomy, however, the risk of postoperative complications in such patients is not known. Analyzing patients with acute severe UC, we compared the incidence of postoperative complications in patients who failed rescue therapy with cyclosporine or IFX with that in patients who received intravenous (IV) corticosteroids alone...
January 2014: Inflammatory Bowel Diseases
Jun Shen, Zhi-Xiang Zuo, Ai-Ping Mao
BACKGROUND: Whether probiotics are beneficial at all stages of treatment in inflammatory bowel disease or superior to placebo remains controversial. METHODS: Two reviewers independently selected randomized controlled trials comparing probiotics with controls in inflammatory bowel disease and extracted data related to remission/response rates, relapse rates, and adverse events. Subanalyses were also performed. RESULTS: Twenty-three randomized controlled trials with a total of 1763 participants met the inclusion criteria...
January 2014: Inflammatory Bowel Diseases
Brian G Feagan, John W D McDonald, Remo Panaccione, Robert A Enns, Charles N Bernstein, Terry P Ponich, Raymond Bourdages, Donald G Macintosh, Chrystian Dallaire, Albert Cohen, Richard N Fedorak, Pierre Paré, Alain Bitton, Fred Saibil, Frank Anderson, Allan Donner, Cindy J Wong, Guangyong Zou, Margaret K Vandervoort, Marybeth Hopkins, Gordon R Greenberg
BACKGROUND & AIMS: Methotrexate and infliximab are effective therapies for Crohn's disease (CD). In the combination of maintenance methotrexate-infliximab trial, we evaluated the potential superiority of combination therapy over infliximab alone. METHODS: In a 50-week, double-blind, placebo-controlled trial, we compared methotrexate and infliximab with infliximab alone in 126 patients with CD who had initiated prednisone induction therapy (15-40 mg/day) within the preceding 6 weeks...
March 2014: Gastroenterology
Jonathan P Terdiman, Claudia B Gruss, Joel J Heidelbaugh, Shahnaz Sultan, Yngve T Falck-Ytter
No abstract text is available yet for this article.
December 2013: Gastroenterology
Sieglinde Angelberger, Walter Reinisch, Athanasios Makristathis, Cornelia Lichtenberger, Clemens Dejaco, Pavol Papay, Gottfried Novacek, Michael Trauner, Alexander Loy, David Berry
OBJECTIVES: Fecal microbiota transplantation (FMT) from healthy donors, which is an effective alternative for treatment of Clostridium difficile-associated disease, is being considered for several disorders such as inflammatory bowel disease, irritable bowel syndrome, and metabolic syndrome. Disease remission upon FMT is thought to be facilitated by an efficient colonization of healthy donor microbiota, but knowledge of the composition and temporal stability of patient microbiota after FMT is lacking...
October 2013: American Journal of Gastroenterology
Guillaume Bouguen, Barrett G Levesque, Brian G Feagan, Arthur Kavanaugh, Laurent Peyrin-Biroulet, Jean-Frederic Colombel, Stephen B Hanauer, William J Sandborn
The traditional management of Crohn's disease, which is based on progressive, step-wise treatment intensification with re-evaluation of response according to symptoms, does not improve long-term outcomes of Crohn's disease and places patients at risk for bowel damage. The introduction of novel therapies and the development of new approaches to treatment in rheumatoid arthritis led to better outcomes for patients. Prominent among these is a "treat to target" strategy that is based on regular assessment of disease activity by using objective clinical and biological outcome measures and the subsequent adjustment of treatments...
June 2015: Clinical Gastroenterology and Hepatology
David T Rubin, Dezheng Huo, Jami A Kinnucan, Mina S Sedrak, Nicole E McCullom, Alana P Bunnag, Elin P Raun-Royer, Russell D Cohen, Stephen B Hanauer, John Hart, Jerrold R Turner
BACKGROUND & AIMS: An association between inflammatory activity and colorectal neoplasia (CRN) has been documented in patients with ulcerative colitis (UC). However, previous studies did not address the duration of inflammation or the effects of therapy on risk for CRN. We investigated the effects of inflammation, therapies, and characteristics of patients with UC on their risk for CRN. METHODS: We collected data from 141 patients with UC without CRN (controls) and 59 matched patients with UC who developed CRN (cases), comparing disease extent and duration and patients' ages...
December 2013: Clinical Gastroenterology and Hepatology
R Khanna, B D Sattin, W Afif, E I Benchimol, E-J Bernard, A Bitton, B Bressler, R N Fedorak, S Ghosh, G R Greenberg, J K Marshall, R Panaccione, E G Seidman, M S Silverberg, A H Steinhart, R Sy, G Van Assche, T D Walters, W J Sandborn, B G Feagan
BACKGROUND: Tumour necrosis factor (TNF)-antagonists have an established role in the treatment of inflammatory bowel diseases (IBDs), however, subtherapeutic drug levels and the formation of anti-drug antibodies (ADAs) may decrease their efficacy. AIM: The evidence supporting the use of therapeutic drug monitoring (TDM) based clinical algorithms for infliximab (IFX) and their role in clinical practice will be discussed. METHODS: The literature was reviewed to identify relevant articles on the measurement of IFX levels and antibodies-to-infliximab...
September 2013: Alimentary Pharmacology & Therapeutics
Aude Bressenot, Karel Geboes, Jean-Michel Vignaud, Jean-Louis Guéant, Laurent Peyrin-Biroulet
Inflammatory bowel disease is characterized by 2 major entities: Crohn's disease (CD) and ulcerative colitis (UC). In clinical practice, separation of UC and CD has been based on a variety of clinical features, symptoms, endoscopic and radiological, gross and microscopic characteristics. The microscopic diagnosis of inflammatory bowel disease is based on a combination of 2 types of lesions: architectural abnormalities and inflammatory features. However, microscopic distinction between these 2 entities can be difficult and often results in an interim diagnosis of "indeterminate colitis...
July 2013: Inflammatory Bowel Diseases
2014-04-11 12:35:15
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"